Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000523219 | SCV000620509 | pathogenic | not provided | 2018-04-10 | criteria provided, single submitter | clinical testing | The R6469X variant in the NEB gene has not been reported previously as a pathogenic variant nor as a benign variant, to our knowledge. This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. The R6469X variant is not observed in large population cohorts (Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome Variant Server). We interpret R6469X as a pathogenic variant. |
Labcorp Genetics |
RCV000984199 | SCV001592118 | pathogenic | Nemaline myopathy 2 | 2023-06-11 | criteria provided, single submitter | clinical testing | ClinVar contains an entry for this variant (Variation ID: 451764). This variant has not been reported in the literature in individuals affected with NEB-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Arg6469*) in the NEB gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in NEB are known to be pathogenic (PMID: 25205138). For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV003476223 | SCV004200117 | likely pathogenic | Arthrogryposis multiplex congenita 6 | 2023-09-15 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000984199 | SCV001132256 | likely pathogenic | Nemaline myopathy 2 | 2017-10-20 | no assertion criteria provided | clinical testing |